5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer

References

• Chuah LH, Roberts CJ, Billa N, et al. (2014). Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles. Colloids Surf B Biointerfaces 116:228–36
   PubMed Web of Science ®Google Scholar
• Cirstoiu-Hapca A, Buchegger F, Bossy L, et al. (2009). Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci 38:230–7
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Danesi R, Falcone A, et al. (2001). Relationship between 5-fluorouracil disposition, toxicity and dihydropy rimidine dehydrogenase activity in cancer patients. Ann Oncol 12:1301–6
   PubMed Web of Science ®Google Scholar
• Fata F, Ron IG, Kemeny N, et al. (1999). 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86:1129–34
   PubMed Web of Science ®Google Scholar
• Ghorab DM, Amin MM, Khowessah OM, Tadros MI. (2011). Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ɛ-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats. Drug Deliv 18:523–35
   PubMed Web of Science ®Google Scholar
• Guo J, Verma UN, Tripathy D, et al. (2006). Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil1. Acta Pharmacol Sin 27:1375–81
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Green SJ, Ravdin PM, et al. (2005). Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23:8313–21
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK, Ganesh N, et al. (2010). Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine Nanotechnol Biol Med 6:179–90
   PubMed Web of Science ®Google Scholar
• Krishnaiah Y, Satyanarayana S. (2001). Colon-specific drug delivery systems. Advances in controlled and novel drug delivery. New Delhi, India: CBS Publishers and Distributors, 89–119
   Google Scholar
• Levine DS, Raisys VA, Ainardi V. (1987). Coating of oral beclomethasone dipropionate capsules with cellulose acetate phthalate enhances delivery of topically active antiinflammatory drug to the terminal ileum. Gastroenterology 92:1037–44
   PubMed Web of Science ®Google Scholar
• Li F, Zhao X, Wang H, et al. (2015). Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models. Adv Funct Mater 25:788–98
   Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. (2003). 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–8
   PubMed Web of Science ®Google Scholar
• Michor F, Iwasa Y, Lengauer C, Nowak MA. (2005). Dynamics of colorectal cancer. Semin cancer Biol 15:484–93
   PubMed Web of Science ®Google Scholar
• Nair L, Jagadeeshan S, Nair SA, Kumar GV. (2011). Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomedicine 6:1685–97
   PubMed Web of Science ®Google Scholar
• Ozols RF, Herbst RS, Colson YL, et al. (2006). Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J Clin Oncol 25:146–62
   PubMed Web of Science ®Google Scholar
• Parker WB, Cheng YC. (1990). Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48:381–95
   PubMed Web of Science ®Google Scholar
• Prabhaharan M, Mano JF. (2004). Chitosan-based particles as controlled drug delivery systems. Drug Deliv 12:41–57
   Web of Science ®Google Scholar
• Radulovic S, Miller G, Schally AV. (1991). Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res 51:6006–9
   PubMed Web of Science ®Google Scholar
• Rai G, Yadav AK, Jain NK, Agrawal GP. (2014). Eudragit-coated dextran microspheres of 5-fluorouracil for site-specific delivery to colon. Drug Deliv. [Epub ahead of print]. DOI:10.3109/10717544.2014.913733
   Web of Science ®Google Scholar
• Rasmussen S, Bondesen S, Hvidberg E, et al. (1982). 5-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 83:1062–70
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Green SB, Burger PC, et al. (1992). A randomized comparison of intra-arterial versus intravenous with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76:772–81
   PubMed Web of Science ®Google Scholar
• Tummala S, Kumar MS, Gowthamarajan K, et al. (2014). Preparation, physicochemical characterization and in vitro evaluation of oxaliplatin solid lipid nanoparticles for the treatment of colorectal cancer. Indo Am J Pharm Res 4:3579–87
   Google Scholar
• Tummala S, Gowthamarajan K, Satish Kumar MN, Wadhwani A. (2015a). Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors. Drug Delivery. [Epub ahead of print]. DOI:10.3109/10717544.2015.1084400
   Web of Science ®Google Scholar
• Tummala S, Kumar MS, Prakash A. (2015b). Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J 23:308–14
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Haasjes J, Richel DJ, et al. (2000). Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:4705–12
   PubMed Web of Science ®Google Scholar
• Vivek R, Thangam R, NipunBabu V, et al. (2014). Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. ACS Appl Mater Interfaces 6:6469–80
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang X, Liu T, et al. (2014). Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer. Drug Deliv. [Epub ahead of print]. DOI:10.3109/10717544.2014.916768
   Web of Science ®Google Scholar